Pharmacy benefit managers overcharged for specialty generic medications — in many cases by hundreds and thousands of percent ...

At a public meeting held on January 15, 2025, the Federal Trade Commission (FTC) summarized the Second Interim Staff Report ...

Mintz’s Health Law and Antitrust teams actively monitor federal and state regulatory and legislative developments in the PBM ...

A bipartisan, bicameral group of lawmakers is calling on the Federal Trade Commission (FTC) to vote in favor of releasing an interim staff report on pharmacy benefit managers (PBM). Sens.

The FTC released a 60-page report Tuesday targeting the biggest three pharmacy benefit managers, claiming the companies hiked ...

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.

“The FTC staff’s second interim report finds that ... CEO of 46booklyn — said he’s glad not to be the only one working to expose PBM practices. He said he launched 46brooklyn in 2018 ...

The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying the major industry middlemen generate billions in revenue through ...

Pharmacy benefit managers are the middlemen in the prescription drug market. The Federal Trade Commission reports the revenue of four PBMs exceeds $1 trillion and they control 86% of the market.

An FTC official told reporters the $7.3 billion figure could be an underestimation. PBM-affiliated pharmacy dispensing revenue increased at an annual growth rate of 42% from 2017 to 2021 ...

The FTC’s investigation into PBM practices began in 2022. Last summer, the agency released a scathing interim report on the industry. It detailed how increasing concentration enabled the three ...